Patent 10280424 was granted and assigned to Mologen AG on May, 2019 by the United States Patent and Trademark Office.
The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.